Supernus Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
642.90 |
641.08 |
742.01 |
836.73 |
931.66 |
1,077.65 |
| Przychód Δ r/r |
0.00% |
-0.28% |
15.74% |
12.77% |
11.35% |
15.67% |
| Przychód (min) |
640.53 |
630.59 |
704.41 |
821.95 |
903.05 |
1,044.56 |
| Przychód (max) |
646.53 |
660.34 |
828.77 |
851.52 |
987.54 |
1,142.28 |
| EBITDA (średnia) |
164.40 |
163.93 |
189.74 |
213.96 |
238.24 |
275.57 |
| EBIT (średnia) |
102.14 |
101.85 |
117.89 |
132.94 |
148.02 |
171.21 |
| EBIT % |
15.89% |
15.89% |
15.89% |
15.89% |
15.89% |
15.89% |
| Zysk netto (średni) |
161.91 |
93.82 |
123.11 |
188.77 |
285.39 |
366.53 |
| Zysk netto % |
25.18% |
14.64% |
16.59% |
22.56% |
30.63% |
34.01% |
| EPS (średnia) |
2.87 |
1.68 |
2.20 |
3.37 |
5.10 |
6.55 |
| Liczba analityków (Przychody) |
4 |
3 |
4 |
4 |
2 |
3 |
| Liczba analityków (EPS) |
2 |
2 |
2 |
2 |
1 |
1 |
| symbol |
SUPN |
SUPN |
SUPN |
SUPN |
SUPN |
SUPN |